Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Monday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Antero Midstream, Chewy, Domino's Pizza, eHealth, First Solar, Kraft Heinz, Newmont, Square, Tilray and...
Thursday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, American Electric Power, Analog Devices, CenturyLink, Dish Network, Herbalife, NextEra Energy, NRG Energy,...
Monday's top analyst upgrades, downgrades and initiations included Alphabet, Apple, Bank of America, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers and JD.com.
Gilead and Galapagos each saw shares shoot up on Monday after the companies announced a new collaboration.
The top analyst upgrades, downgrades and initiations seen on Friday included Arista Networks, Carlyle, F5 Networks, Intuit, Oracle, Salesforce, Viacom, Viking Therapeutics and Wells Fargo.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
The top analyst upgrades, downgrades and initiations seen on Thursday include American Superconductor, Galapagos, Humana, Intel, Philips Electronics, Pinduoduo, Qualcomm and Wayfair.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Monday's top analyst upgrades, downgrades and initiations include Atmel, BlackBerry, Citigroup, DSW, JC Penney, 2U, TD Ameritrade and Vertex Pharmaceuticals.
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Source: ThinkstockOf the nine initial public offerings (IPO) on last week’s calendar, six made it out the door, and for the second week in a row the largest IPO was the general partner of a natural...
Source: ThinkstockWith 14 initial public offerings (IPO) on the calendar for last week, it was almost inevitable that some would fall by the wayside. As it turns out only 8 made the leap onto the...